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OBJECTIVES In this dose-finding study, we sought to compare fondaparinux with enoxaparin in patients
with acute coronary syndromes (ACS).
BACKGROUND Fondaparinux is a synthetic pentasaccharide that selectively inhibits activated clotting factor
X. It has been demonstrated as effective in preventing thromboembolic complications in
orthopedic surgery.
METHODS Four doses fondaparinux (2.5, 4, 8, or 12 mg once daily) and enoxaparin (1 mg/kg twice daily)
were compared, both given for three to seven days, in patients with ACS without persistent
ST-segment elevation.
RESULTS The rates of the combined primary end point of death, myocardial infarction, or recurrent
ischemia after nine days were 27.9%, 35.9%, 34.7%, 30.3%, and 35.7% in patients allocated
to fondaparinux doses of 2.5, 4, 8, and 12 mg and enoxaparin, respectively (p  NS). In the
per-protocol analysis (929 patients who received adequate study drug and had adequate
ST-segment monitoring), these figures were 30.0%, 43.5%, 41.0%, 34.8%, and 40.2%. Again,
no dose response was observed. The lowest event rates were observed in the 2.5-mg
fondaparinux group, which had significantly lower rates than the enoxaparin group as well as
for 4 and 8 mg fondaparinux in the per-protocol analysis (p  0.05). Bleeding rates were low
and not different among the patient groups. No differences were observed in fondaparinux
concentrations in patients with or without death, myocardial infarction, recurrent ischemia,
or bleeding events.
CONCLUSIONS This dose-finding study revealed no dose response for different fondaparinux doses ranging
from 2.5 to 12 mg subcutaneously and suggests that the efficacy and safety of fondaparinux
may be similar to that of enoxaparin. Further studies with fondaparinux in ACS might
include the lowest dose (2.5 mg) investigated in this study. (J Am Coll Cardiol 2004;43:
2183–90) © 2004 by the American College of Cardiology Foundationc
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antithrombotic therapy with unfractionated heparin or
ow-molecular-weight heparin (LMWH) and aspirin is part
f the standard care for patients with acute coronary
yndromes (ACS) without persistent ST-segment elevation
1). Low-molecular-weight heparin has become the antico-
gulant of choice in these patients, as it can be administered
ubcutaneously without the need for laboratory monitoring
nd subsequent dosage adaptations (1). However, despite
uch treatment, 5% to 15% of patients still develop myo-
ardial infarction (MI) or die within the first weeks (2).
Fondaparinux is a new selective inhibitor of activated
From the *Thoraxcenter, Erasmus Medical Center, Rotterdam, The Netherlands;
Organon, Oss, The Netherlands; ‡CHR Citadelle, Luik, Belgium; §Academic
edical Center, Amsterdam, The Netherlands; Instytut Kardiologii, Warszawa,
oland; ¶Medisch Centrum, Alkmaar, The Netherlands; #Hopital Bichat, Paris,
rance; **University Hospital Gasthuisberg, Leuven, Belgium; and ††Sta¨dtischen
liniken, Kassel, Germany. The institutions and investigators participating in the
tudy are listed in the Appendix.
Manuscript received March 12, 2003; revised manuscript received February 20,s004, accepted February 24, 2004.lotting factor X, a key enzyme in the coagulation pathway.
t is a synthetic pentasaccharide that is structurally related to
he antithrombin-binding site of heparin and LMWH. In
ontrast to heparins, which interact with several plasma
omponents, fondaparinux selectively binds to antithrombin
nd causes rapid inhibition of activated factor X. It has a
alf-life of 15 h, with linear pharmacokinetics and low
ntra- and inter-individual variability, thus allowing once
aily administration without laboratory monitoring (3,4).
ecent studies in patients undergoing major orthopedic
urgery have shown a significant reduction of venous throm-
oembolic events in fondaparinux-treated patients com-
ared with those treated with LMWH (4–8). In patients
ith evolving MI treated with alteplase, fondaparinux
ielded similar early coronary patency and a trend toward
ess reocclusion (p  0.065), as compared with unfraction-
ted heparin (9). Consequently, fondaparinux might also be
n alternative to LMWH in the treatment of coronary
yndromes without persistent ST-segment elevation.
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Fondaparinux in ACS June 16, 2004:2183–90ence, a dose-finding study was conducted in patients with
uch acute coronary syndromes, comparing four different
osages of fondaparinux with the LMWH enoxaparin.
ETHODS
tudy patients. Consecutive patients older than 21 years
nd weighing 120 kg with ACS without persistent ST-
egment elevation were eligible for the study. Patients were
equired to have angina at rest or during minimal exertion,
ith the last episode within 24 h before enrollment and with
ynamic ST-segment changes or ST-segment depression
0.1 mV) and/or cardiac troponin T or I concentrations
bove 0.1 ng/ml. Major exclusion criteria were ST-segment
levation requiring reperfusion therapy, an electrocardio-
raphic (ECG) pattern making interpretation of ST-T
hanges unreliable, or the intention to proceed to percuta-
eous coronary intervention (PCI) within 24 h or coronary
rtery bypass graft surgery (CABG) within 48 h. Patients
ere also excluded if they had more than 12 h of therapeutic
nticoagulant treatment, contraindications for anticoagulant
reatment (e.g., bleeding tendency), uncontrolled hyperten-
ion, serum creatinine over 160 mol/l, or platelet counts
100  109/l. All patients gave written, informed consent.
tudy design. Patients were randomized to one of four
ondaparinux dosages or enoxaparin in blocks of five through a
entral computerized service. Treatment was double-blind,
sing a double-dummy technique, and was administered for a
inimum of three days and a maximum of seven days, to allow
evascularization procedures or early patient discharge. A
2-lead continuous computer-assisted ECG monitoring sys-
em (Mortara Inc., Milwaukee, Wisconsin) was used during
he first 24 to 48 h to detect (silent) myocardial ischemia
10,11). Efficacy and safety outcomes were reported for a
eriod of 30 days. The primary efficacy evaluation was at day 9.
All potential study outcomes were reviewed by a central
djudication committee, and ECG recordings were ana-
yzed by a central core laboratory. Both were blinded as to
atient allocation. The Data and Safety Monitoring Board
egularly reviewed the efficacy and safety outcomes. Discon-
inuation of a study arm was to be considered if the
ncidence of major bleeding was higher than could be
xpected, or when a significant difference in symptomatic
ecurrent ischemic events between the enoxaparin and any
ondaparinux treatment group was observed. The study was
Abbreviations and Acronyms
ACS  acute coronary syndromes
CABG  coronary artery bypass graft surgery
CK-MB  creatine kinase-MB fraction
ECG  electrocardiographic
LMWH  low-molecular-weight heparin
MI  myocardial infarction
PCI  percutaneous coronary intervention
PENTUA  Pentasaccharide in Unstable Angina studyonducted in accordance with the Declaration of Helsinki, She International Conference on Harmonization and Good
linical Practice Guidelines, and was approved by the local
nstitutional review boards.
reatment regimens. Patients in the fondaparinux (Arixtra,
V Organon, Oss, the Netherlands; Sanofi-Synthe´labo, Paris,
rance) groups received one of four dosages (2.5, 4, 8, or 12
g) once daily subcutaneously, with the first dose given
ntravenously. Patients with a body weight 50 kg received
ower dosages: 2, 3, 6, or 9 mg, and those heavier than 100 kg
eceived 3, 5, 10, or 15 mg. The selection of the lowest dosage
f 2.5 mg was based on the consideration that this dosage was
ffective as thromboprophylaxis in high-risk patients (4),
hereas dosages of 4, 8, or 12 mg, as administered in the
ynthetic Pentasaccharide as an Adjunct to Fibrinolysis in
T-Elevation Acute Myocardial Infarction (PENTALYSE)
tudy (9), appeared equally effective. The latter suggested that
he minimally effective dose of fondaparinux would be lower
han 4 mg. The highest dosage of 12 mg was selected, because
n studies of healthy volunteers, higher dosages showed a
endency toward hemorrhage at puncture sites. Patients in the
noxaparin (Clexane/Lovenox, Aventis Pharmaceuticals,
ridgewater, New York) group received 1 mg/kg twice daily
ubcutaneously, according to the manufacturer’s instructions
12–14). To ensure double-blinding, fondaparinux-treated pa-
ients also received placebo-enoxaparin injections twice daily,
nd enoxaparin-treated patients received a placebo-
ondaparinux injection once daily, with the first dose give
ntravenously (double-dummy method). In addition, all pa-
ients received 75 to 160 mg/day aspirin, preceded by a loading
ose if indicated.
Study medication was stopped before any coronary inter-
entional procedure. Heparin, glycoprotein IIb/IIIa block-
rs, ticlopidine, and clopidogrel during such intervention
ere allowed. Prohibited concomitant medications were
ral anticoagulants, fibrinolytic agents, LMWH, and ther-
peutic doses of unfractionated heparin other than during
nterventions.
fficacy end points. The primary efficacy end point was
he composite of mortality, acute MI, or recurrent symp-
omatic or asymptomatic myocardial ischemia up to day 9.
n order to distinguish between thrombotic events (possible
ack of efficacy) and bleeding events (possible overdose),
eath related to bleeding was not included in the primary
fficacy end point. Secondary efficacy end points were each
f the components of the primary efficacy end point and
evascularization procedures. In addition, the outcome in
he treatment groups was analyzed at 30 days.
Myocardial infarction was defined as an elevation of
reatine kinase-MB fraction (CK-MB) 2 times the upper
imit of normal (3 times after PCI; 5 times after
ABG) or new Q waves or new left bundle branch block. In
ddition, a more sensitive diagnosis of MI was applied,
ncluding any elevation of CK-MB above the upper limit of
ormal (15).
Recurrent ischemia was defined as at least 1 mm (0.1 mV)T-segment depression for at least 1 min during continuous
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June 16, 2004:2183–90 Fondaparinux in ACS2-lead ECG monitoring (10,11), chest pain in combina-
ion with at least 1 mm (0.1 mV) ST-segment depression or
levation (symptomatic episodes), or re-admission to the
ospital due to unstable angina.
afety end points. The primary safety end point was major
leeding up to day 9. Major bleeding included any overt
leeding associated with death, a life-threatening condition,
re)operation to manage bleeding (retroperitoneal, intracra-
ial, or in another critical organ), or a drop in hemoglobin
f more than 1.2 mmol/l (2.0 g/l) or requiring a transfusion
f 2 U or more of whole blood or packed cells or other
ntervention. Overt bleeding episodes that did not qualify as
ajor were considered a secondary safety end point (minor
leeding). Minor bleeding at subcutaneous injection sites
as considered not clinically relevant and was not included
n this safety end point.
harmacokinetics. Plasma concentrations of fondaparinux
mg/l) were determined in samples obtained at baseline, at
to 2 h after the dose on several days during treatment, and
efore dosing on day 3. Measurements were performed in a
entral laboratory by a validated assay based on the anti-Xa
ctivity of the antithrombin III-fondaparinux complex. In
his assay, the amount of hydrolysis of a chromogenic
ubstrate, which is inversely proportional to the fondapa-
inux concentration, is determined after the addition of a
nown quantity of factor Xa, in the presence of an excess of
ntithrombin.
tatistical analyses. Based on an expected event rate for
he primary efficacy end point of 36% in the highest dose
roup and 50% in the lowest dose group, it was estimated
hat the study would have a power of 80%, with one-sided
ype I error of 2.5%, to detect a positive dose-response
elationship for fondaparinux if 190 evaluable patients per
roup were available (Cochran-Armitage trend test). To
llow for missing primary outcome data, the sample size was
et at 215 patients per group. The analysis was by the
ntention-to-treat principle for all randomized patients,
egardless of whether they received any study drug or not. In
ddition, a per-protocol analysis was defined as the primary
nalysis for efficacy in order to select a dose for further
tudies with fondaparinux in ACS.
For the per-protocol analysis, the following exclusion
riteria were prespecified: patients with incomplete admin-
stration of study treatment (missing one or more active
njections during the first 3 days), use of prohibited con-
omitant medication, or inadequate continuous ECG mon-
toring (less than 12 h recording) in the absence of a
ymptomatic end point. The safety analysis was based on all
atients who received study medication.
Incidences and their 95% confidence intervals were cal-
ulated for the primary efficacy and safety end points.
airwise comparisons between treatment groups were per-
ormed using the Fisher exact test. The time to the first
vent was analyzed for the primary efficacy parameter using
aplan-Meier analysis. Analyses for trend over dosages
ere performed using the Cochran-Mantel-Haenszel test ar the Cochran-Armitage test for trend, as appropriate.
hen applicable, odds ratios and their 95% confidence
ntervals were calculated to estimate the impact of covari-
tes. No corrections were made for multiple comparisons in
his dose-finding study.
ESULTS
tudy population. During the period of July 1999 to
anuary 2001, a total of 1,138 patients were randomized
intention-to-treat population), of whom 929 had complete
ollow-up information, including adequate ST-segment
onitoring and three days of treatment with study drug
per-protocol analysis). Four patients did not receive the
llocated dose of fondaparinux or enoxaparin.
This report describes the efficacy and safety results for the
ntention-to-treat group (n  1,138), as well as efficacy for
he per-protocol analysis (n  929). The baseline charac-
eristics and outcome patterns were similar in the different
nalyses (Table 1): 47% of patients had dynamic ECG
hanges at baseline, 54% showed ST-segment depression,
1% had elevated cardiac troponin T (0.1 ng/ml), 22% of
atients (n  252) had troponin T levels 0.3 ng/ml, and
0% had both elevated troponin (0.1 ng/ml) and an
bnormal ST-segment. At enrollment in the study, 58% of
atients had already received aspirin, 42% had received
nfractionated heparin or LMWH, and 5% had received
ipid-lowering drugs. The fondaparinux and enoxaparin
reatment groups were comparable regarding these
haracteristics. After randomization, all patients received
spirin and most patients received nitrates (95%) and
eta-blockers (91%). Lipid-lowering drugs were given in
4%: angiotensin-converting enzyme inhibitors in 45%,
alcium channel blockers in 40%, thienopyridines in 19%,
nd glycoprotein IIb/IIIa receptor blockers in 3.4% of
atients. There were no significant differences in medication
mong the treatment groups.
Adequate ST-segment monitoring data were not avail-
ble during at least 12 h in 71 patients who did not show
ymptomatic ischemia, MI, or death within nine days.
urthermore, 21 patients received pre-study medication
hat was not allowed, 110 patients received prohibited
edication during the first nine days of the study, and 22
atients had one or more missed injections with active study
rug during the first three days. As specified in the protocol
f this dose-finding study, these patients were excluded
rom the per-protocol analysis.
reatment. The median duration of study treatment was
ve days (range three to eight days). Treatment was discon-
inued in 211 patients (178 patients in the per-protocol
roup) because of the occurrence of an end point (n  19
1.7%]), a serious adverse event (n  6 [0.5%]), urgent
oronary revascularization (n  54 [4.7%]), unusual bleed-
ng (n  6 [0.5%]), withdrawal of consent (n  4 [0.3%]),
nd other reasons, including planned coronary revascular-
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Fondaparinux in ACS June 16, 2004:2183–90zation (n  122 [10.7%]). Discontinuation of study treat-
ent was similar among the treatment groups.
fficacy. Mortality was low (1.1%), and no fatal bleedings
ccurred. Myocardial infarction was reported in 1.7%, using
threshold of CK-MB 2 times the upper limit of normal,
nd in 7.0%, using the more sensitive definition (including
ny CK-MB elevation) (15).
No dose response was observed among the fondaparinux
osage groups, neither in the intention-to-treat analysis nor
n the per-protocol analysis (test for trend: p  0.70 and
 0.40, respectively). The lowest event rate in the
er-protocol analysis was observed in the 2.5 mg fondapa-
inux groups, which had a significantly lower rate than that
n the 4 or 8 mg fondaparinux and enoxaparin groups (Fig.
). The most frequent event was recurrent ischemia, as
etected by continuous 12-lead ECG monitoring. In the
ntention-to-treat analysis, the same pattern was apparent,
Table 1. Baseline Characteristics
2.5
Intention-to-treat population (n) 229
Demographics
Mean age (yrs) 62
Male gender (%) 63
Mean body weight (kg) 78
Clinical characteristics
Dynamic ST-segment depression (%) 46
ST-segment depression (%) 55
Troponin-positive (%) 42
History of
Myocardial infarction (%) 24
Angina (%) 52
Heart failure (%) 6
PTCA (%) 6
CABG (%) 9
Hypertension (%) 50
Hypercholesterolemia (%) 43
Diabetes (%) 21
Currently smoking (%) 25
Per-protocol population (n) 203
Demographics
Mean age (yrs) 62
Male gender (%) 61
Mean body weight (kg) 78
Clinical characteristics
Dynamic ST-segment changes (%) 46
ST-segment depression (%) 57
Troponin-positive (%) 43
History of
Myocardial infarction (%) 23
Angina (%) 52
Heart failure (%) 5
PTCA (%) 5
CABG (%) 8
Hypertension (%) 52
Hypercholesterolemia (%) 43
Diabetes (%) 22
Currently smoking (%) 25
Data are presented for all randomized patients (intention-to
CABG  coronary artery bypass graft surgery; PTCA ut the differences were not statistically significant. Differ- nnces in combined events (death, MI, and recurrent isch-
mia), as observed among the treatment groups, were
lready apparent during the first three days and sustained
hroughout the 30-day study period (Fig. 2). These differ-
nces were mainly due to a lower rate of recurrent ischemia.
here were no significant differences in death or death and
I at 9 or 30 days (Table 2). At 30-day follow-up,
ortality rates (intention to treat) were 1.3%, 3.2%, 1.3%,
.6%, and 1.4%, respectively, for 2.5, 4, 8, and 12 mg
ondaparinux and enoxaparin. Per protocol, these figures
ere 1.5%, 3.9%, 0.6%, 3.2%, and 1.6%, respectively. For
he combined end point of death, MI, and recurrent
schemia, the 30-day outcomes were 32.3%, 38.2%, 36.0%,
3.8%, and 38.7% (intention to treat) versus 33.8%, 44.9%,
2.4%, 37.8%, and 43.6% (per protocol), respectively.
In-hospital revascularization procedures were performed
n 18% (PCI) and 3% (CABG) of patients (Table 2). Again,
Fondaparinux
Enoxaparin
1 mg/kg4 mg 8 mg 12 mg
220 225 234 230
61.3 62.0 61.1 60.3
68.6 65.8 70.5 67.4
79.3 78.1 79.1 79.2
46.8 49.8 48.7 46.5
58.6 52.9 50.0 52.6
38.7 44.9 40.2 37.7
36.1 21.6 28.4 21.4
59.8 53.6 53.0 51.5
5.9 5.0 4.2 3.5
17.4 8.6 9.7 14.8
9.1 11.3 5.1 8.3
47.0 51.8 50.0 47.6
46.1 45.9 46.6 45.9
14.6 17.1 14.4 16.6
35.6 31.8 34.7 29.7
177 173 187 189
61.1 61.9 61.0 60.5
70.1 68.2 70.1 66.1
79.6 78.9 79.5 79.1
42.4 48.0 48.7 47.6
60.5 57.2 50.8 55.6
37.5 47.2 40.5 37.4
36.7 19.7 29.9 21.7
63.3 49.7 54.0 52.9
5.6 4.0 4.3 3.7
16.9 6.9 8.6 14.3
9.0 7.5 5.9 6.3
49.7 53.2 52.9 48.7
48.6 43.4 45.5 43.4
14.1 16.2 15.0 18.5
35.6 30.8 36.9 25.9
population; top) and the per-protocol analysis (bottom).
taneous coronary intervention.mg
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June 16, 2004:2183–90 Fondaparinux in ACSreatment groups. One patient died five days after PCI; the
ther deaths up to day 9 occurred in patients not undergoing
evascularization. Two MIs were reported within 24 h of
CI, six occurred before PCI or CABG, and nine in
atients not undergoing revascularization. No relationship
as observed between the timing of these events and the
tudy drug.
igure 2. First occurrence of an event (death, myocardial infarction, or
ecurrent ischemia) until 30 days in the five treatment groups (intention-
igure 1. Primary end point: death, myocardial infarction, and recurrent
schemia within nine days in patients treated with fondaparinux or
noxaparin (enox) for the intention-to-treat (upper panel) and per-
rotocol analyses (lower panel). The shaded area of each bar represents
he proportion of patients with death or myocardial infarction. Significant
ifferences were only apparent in the per-protocol analysis, as indicated in
he figure.ro-treat analysis).leeding. The incidence of major and minor bleeding
pisodes is shown in Table 3. Bleeding rates were low, and
o significant differences between the treatment groups
ere observed. No major bleeding episodes occurred in
atients receiving 2.5 mg fondaparinux or enoxaparin.
harmacokinetics. A dose-dependent increase was ob-
erved in both the predose and post-dose fondaparinux
lasma concentrations determined on day 3 of treatment.
he mean post-dose concentrations were 0.41, 0.65, 1.15,
nd 1.61 mg/l for patients receiving 2.5, 4, 8, and 12 mg
ondaparinux, respectively. Within each dosage group, the
ondaparinux plasma concentrations in patients with a
rimary end point were similar to those of patients without
eath, MI, or recurrent ischemia. Similarly, no significant
ifferences were observed in fondaparinux plasma concen-
rations between patients with and those without bleeding.
s expected, there was considerable overlap in plasma
oncentrations among the four dosage groups. When pa-
ients were regrouped according to the post-dose plasma
oncentration at day 3, the lowest rates of death, MI, or
ecurrent ischemia were observed for patients with plasma
oncentrations in the lowest range, whereas no correlation
ith plasma concentration was observed for bleeding events.
ISCUSSION
he Pentasaccharide in Unstable Angina study (PENTUA)
ose-finding study showed no dose response among the four
oses of fondaparinux and suggests overall similar efficacy
nd safety with the synthetic pentasaccharide fondaparinux
nd enoxaparin for management of patients admitted with
CS without persistent ST-segment elevation. No major
leeding events were observed in patients receiving 2.5
g/day fondaparinux or enoxaparin. The absence of a dose
esponse among the four doses of fondaparinux was consis-
ent for different end points, including death, MI, symp-
omatic recurrent ischemia, any recurrent ischemia, and
evascularization.
The lowest event rate (death, MI, and recurrent ischemia)
t day 9, as well as day 30, was observed in patients receiving
.5 mg fondaparinux, which, in the per-protocol analysis at
ay 9, was significantly lower than that with enoxaparin
Fig. 1). However, there is no known physiologic argument
o explain why a lower dose of fondaparinux (2.5 mg) would
e more effective than higher dosages (4 to 12 mg).
ccordingly, the apparent differences among the four dose
roups may be a play of chance, and further studies are
equired to assess whether fondaparinux given as 2.5 mg/
ay, or even lower doses, will be as effective as, or perhaps
uperior to, the usual regimen of enoxaparin in patients with
CS.
ose response. Assessment of the optimal dose regimen is
major challenge in drug development. In patients with
CS, effective therapies have been established, including
spirin, heparin (16,17), LMWH (12,13,18,19), and, more
ecently, clopidogrel (20). Accordingly, we considered it
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Fondaparinux in ACS June 16, 2004:2183–90nethical to include a true placebo group in the present
tudy, and we selected a lowest dose of fondaparinux, which,
ased on other studies, was likely to be effective.
Different dosages of fondaparinux, ranging from 0.75 to
.0 mg, were tested for prevention of deep vein thrombosis
fter total hip replacement (4). In that study, a clear dose
esponse was observed, with low event rates for doses
etween 3.0 and 8.0 mg/day and higher event rates for 0.75
nd 1.5 mg/day fondaparinux. Furthermore, there was a
radual increase in major bleeding complications at increas-
ng dosages of fondaparinux (4). Based on these findings, a
ose of 2.5 mg/day fondaparinux was subsequently tested in
our studies for prevention of venous thromboembolism
fter different types of orthopedic surgery (5–8). Taken
ogether, these studies in more than 7,000 patients consis-
ently showed a 55% relative risk reduction for venous
hromboembolic events (odds ratio 0.45, 95% confidence
nterval 0.37 to 0.54) (21). In the present study, the same
ose (2.5 mg) of fondaparinux appeared to have similar or
lightly better efficacy as enoxaparin for the treatment of
CS without persistent ST-segment elevation.
Table 2. Efficacy End Points
2.5 mg
Intention-to-treat analysis (n) 229
Death 0.9
MI (CK-MB 2 ULN) 0.4
MI (CK-MB ULN) 6.1
Death, MI (CK-MB 2 ULN) 1.3
Death, MI (CK-MB ULN) 7.0
RI (ST) 21.8
Death, MI, RI 27.9
PCI 15.3
CABG 3.1
Per-protocol analysis (n) 203
Death 1.0
MI (CK-MB 2 ULN) 0.5
MI (CK-MB ULN) 6.4
Death, MI (CK-MB 2 ULN) 1.5
Death, MI (CK-MB ULN) 7.4
RI (ST) 23.2
Death, MI, RI 30.0
PCI 14.8
CABG 1.9
Data are presented as percentages of patients with events wit
one or more components of the composite end points. My
fraction (CK-MB) 2 times the upper limit of normal (ULN
include myocardial infarction, defined by CK-MB 2 times
CABG  coronary artery bypass graft surgery; PCI  pe
symptomatic or silent, detected by ischemia monitoring; RI (S
monitoring.
able 3. Bleeding Events
2.5 mg
(n  229)
ajor bleeding event (%) (primary safety parameter) 0
inor bleeding event (%) 3.9ata are presented as percentages.In the PENTALYSE study, fondaparinux was given as
n adjunct to fibrinolytic therapy with alteplase (9). Doses of
, 8, and 12 mg fondaparinux resulted in similar angio-
raphic patency as alteplase with standard unfractionated
eparin for 48 to 72 h. No dose response was observed
mong these fondaparinux doses, as in the present study.
Surprisingly, little difference was observed for major and
inor bleeding complications among the doses tested, and
ondaparinux plasma concentrations were similar in patients
ith and without bleeding, suggesting that fondaparinux
ill be relatively safe at doses up to 12 mg/day.
The absence of a dose response between 2.5 and 12 mg
ondaparinux in PENTUA, as well as similar findings for 4,
, and 12 mg fondaparinux in PENTALYSE (9), suggests
hat all doses were at the flat part at the top of the
ose-response curve for this compound. Therefore, it may
e argued that the optimal dose of fondaparinux in ACS
ight be 2.5 mg. However, when the PENTUA study
as designed, it was argued by some physicians that the 2.5
g dose was already too low to be investigated (22). The
ssumption was made that treatment of arterial thrombosis
Fondaparinux
Enoxaparin
1 mg/kg4 mg 8 mg 12 mg
220 225 234 230
2.3 1.3 0.4 0.4
1.8 2.2 1.7 1.3
5.9 6.7 5.1 5.2
4.1 3.6 2.1 1.7
8.2 8.0 5.6 5.7
29.1 24.9 25.2 27.8
35.9 34.7 30.3 35.7
20.0 17.8 20.5 17.0
2.7 1.8 3.4 3.0
177 173 187 189
2.8 0.6 0.5 0.5
1.7 2.9 2.1 1.6
6.8 8.7 5.9 5.8
4.5 3.5 2.7 2.1
9.6 9.2 6.4 6.3
35.6 31.8 29.9 31.2
43.5 41.0 34.8 40.2
19.5 18.0 19.6 16.5
2.7 2.2 4.0 2.9
days after enrollment. An individual patient may experience
al infarction (MI) is defined by either creatine kinase-MB
ny CK-MB above the ULN (15). The composite end points
LN.
eous coronary intervention; RI  recurrent ischemia, either
episodes detected by continuous 12-lead electrocardiographic
Fondaparinux
Enoxaparin
1 mg/kg
(n  230)
4 mg
(n  220)
8 mg
(n  225)
12 mg
(n  234)
1.4 1.8 0.4 0
3.6 4.0 4.3 4.8hin 9
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June 16, 2004:2183–90 Fondaparinux in ACSas in ACS) would require a higher dose than prevention of
enous thrombosis (as in orthopedic surgery). There are,
owever, sparse data to support this notion. The dosage of
noxaparin, as registered for treatment of ACS (1 mg/kg
wice daily) is about three to five times higher than the dose
sed for prevention of venous thromboembolism after
rthopedic surgery (40 mg/day or 30 mg twice daily).
owever, the dose-finding information on enoxaparin in
CS is limited to one study in 630 patients with ACS (12).
ased on these findings, the dose of 1 mg/kg twice daily was
hosen for subsequent phase III studies and shown to be
ore effective to prevent death, MI, and recurrent ischemia,
s compared with unfractionated heparin infusion (13,14).
arger studies with lower doses of enoxaparin, similar to
hose used in orthopedic surgery, have not been conducted;
hus, it remains uncertain whether lower doses might be
qually effective. In view of its observed efficacy to prevent
eep vein thrombosis (4), we decided to include 2.5 mg
ondaparinux as the lowest dose in the PENTUA study.
ecurrent ischemia, MI, and death. In this study, as in
ther studies (13,14,20,23), the most frequent end point
as recurrent ischemia, whereas MI and death were rela-
ively infrequent. A specific feature of the PENTUA study
s the use of 24-h continuous 12-lead ECG recording to
etect myocardial ischemia. The incidence of symptomatic
nd silent ischemia detected in this manner varied from 30%
o 42% among the treatment groups within the first nine
ays. As in other studies, approximately half of the ischemic
pisodes were silent (11). We required adequate recording
f a continuous 12-lead ECG for the per-protocol analysis
n the present study, because it provides more consistent
ssessment of recurrent ischemia than recurrent chest pain.
n earlier studies, we demonstrated a strong relationship
etween recurrent ischemia and the risk of subsequent MI
11). Thus, an end point of recurrent ischemia in a phase II
ose-finding study is an appropriate choice, while it has also
een chosen as part of the primary end point in larger phase
II studies (2,13,14).
At 30 days, the end point of death or MI varied between
.9% and 6.2%, which is lower than that in some previous
tudies in patients with ACS (2,23–25), but similar to the
ecent findings in the Clopidogrel in Unstable angina to
revent Recurrent Events (CURE) study (20). As expected,
vent rates were higher when the new, more sensitive
uropean Society of Cardiology/American College of Car-
iology consensus definition for MI was applied (15). The
elatively low event rates in the PENTUA study (as in
URE study) are most likely related to the selection of
atients for whom at enrollment the physician decided that
arly revascularization would not be necessary. Nevertheless,
t should be appreciated that the rate of revascularization at
0 days was relatively high, ranging from 31% to 43%
mong the different patient groups. This figure is similar to
ther recent studies in patients with ACS (2,20,24,25).
The apparent lower event rate with 2.5 mg fondaparinuxas mainly due to a lower rate of recurrent ischemia.ifferences in death and MI among the five treatment
roups were small and probably due to chance. For example,
hen comparing 2.5 mg fondaparinux and enoxaparin, the
nd point of death and/or MI was slightly lower in the
ormer group, using a threshold of CK-MB exceeding two
imes the upper limit of normal, and higher using a more
ensitive threshold (Table 2). Similar nonsignificant differ-
nces were observed at 30-day follow-up (data not shown).
et, it should be appreciated that small, statistically not
ignificant differences in phase II studies may relate to
nfavorable outcomes in larger phase III studies (26).
areful monitoring in subsequent studies with fondaparinux
n ACS will be appropriate, particularly in view of the
lightly higher mortality in patients receiving fondaparinux.
tudy limitations. It should be appreciated that this was a
hase II study designed to determine the dose for future
tudies with fondaparinux in patients with ACS. Thus, no
efinite conclusions about the relative benefit of fondapa-
inux versus enoxaparin can be drawn. Other limitations
nclude the missing data for ECG monitoring and use of
edications not allowed in the protocol in some of the
atients. Multiple comparisons were made using different
nd points on an intention-to-treat as well as per-protocol
nalysis. Thus, the statistically significant findings may be
ue to chance. However, it is not likely that these limita-
ions have had a significant impact on the outcome of the
tudy, as the absence of a dose-response relationship was
pparent both in the intention-to-treat and per-protocol
nalyses, whereas lower event rates at nine days in patients
llocated to 2.5 mg fondaparinux were consistently observed
n different analyses at days 9 and 30.
onclusions. This phase II dose-finding study indicates
hat fondaparinux in dosages between 2.5 and 12 mg/day
ay have similar efficacy as enoxaparin to prevent early
ecurrent ischemia, MI, or death in patients with ACS not
ndergoing early revascularization (48 h). Bleeding com-
lications were infrequent. These encouraging results
hould be a basis for subsequent phase III studies with
ondaparinux in patients with ACS, including patients
ho will undergo early coronary revascularization. In such
tudies, a 2.5 mg/day fondaparinux regimen should be
nvestigated in combination with aspirin, clopidogrel, and
lycoprotein IIb/IIIa receptor blockers, as currently recom-
ended (1).
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